J Heart Lung Transplant 2009;28: 989-1049 HEART TRANSPLANTATION Overall ISHLT 2009.

Slides:

Advertisements

Similar presentations

HEART TRANSPLANTATION

Advertisements

Donors Per Million Population

© 2008 Pearson Addison Wesley. All rights reserved Chapter Seven Costs.

Properties Use, share, or modify this drill on mathematic properties. There is too much material for a single class, so you’ll have to select for your.

OPTN Modifications to Heart Allocation Policy Implemented July 12, 2006 Changed the allocation order for medically urgent (Status 1A and 1B) patients Policy.

2002 ISHLT HEART TRANSPLANTATION Pediatric Recipients.

HEART-LUNG TRANSPLANTATION Overall ISHLT 2006 J Heart Lung Transplant 2006;25:

2002 ISHLT HEART TRANSPLANTATION Overall ISHLT NUMBER OF HEART TRANSPLANTS REPORTED BY YEAR * Numbers may be low due to delayed reporting. Number.

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2006 J Heart Lung Transplant 2006;25:

HEART-LUNG TRANSPLANTATION Overall ISHLT 2005 J Heart Lung Transplant 2005;24:

HEART TRANSPLANTATION Overall ISHLT 2006 J Heart Lung Transplant 2006;25:

HEART TRANSPLANTATION Overall ISHLT 2008 J Heart Lung Transplant 2008;27:

HEART TRANSPLANTATION Pediatric Recipients ISHLT 2006 J Heart Lung Transplant 2006;25:

2004 ISHLT J Heart Lung Transplant 2004; 23: HEART TRANSPLANTATION Pediatric Recipients.

2002 ISHLT J Heart Lung Transplant 2002; 21: HEART TRANSPLANTATION Overall.

J Heart Lung Transplant 2009;28: LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2009.

2002 ISHLT J Heart Lung Transplant 2002; 21: HEART-LUNG TRANSPLANTATION Overall.

2004 ISHLT J Heart Lung Transplant 2004; 23: HEART-LUNG TRANSPLANTATION Overall.

2001 THE REGISTRY OF THE INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION: EIGHTEENTH ANNUAL REPORT.

HEART TRANSPLANTATION Overall ISHLT 2007 J Heart Lung Transplant 2007;26:

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2008 J Heart Lung Transplant 2008;27:

2004 ISHLT J Heart Lung Transplant 2004; 23: LUNG TRANSPLANTATION Pediatric Recipients.

J Heart Lung Transplant 2009;28: HEART TRANSPLANTATION Pediatric Recipients ISHLT 2009.

J Heart Lung Transplant 2009;28: LUNG TRANSPLANTATION Overall ISHLT 2009.

2003 ISHLT J Heart Lung Transplant 2003; 22: HEART TRANSPLANTATION Overall.

HEART-LUNG TRANSPLANTATION

2003 ISHLT J Heart Lung Transplant 2003; 22: LUNG TRANSPLANTATION Pediatric Recipients.

2003 ISHLT J Heart Lung Transplant 2003; 22: HEART TRANSPLANTATION Pediatric Recipients.

2003 ISHLT J Heart Lung Transplant 2003; 22: HEART-LUNG TRANSPLANTATION Overall.

LUNG TRANSPLANTATION Pediatric Recipients 2011 ISHLT J Heart Lung Transplant Oct; 30 (10):

2001 J Heart Lung Transplant 2001; 20: ; 2002: 21: THE REGISTRY OF THE INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION: EIGHTEENTH.

HEART-LUNG TRANSPLANTATION Overall ISHLT 2008 J Heart Lung Transplant 2008;27:

2002 ISHLT J Heart Lung Transplant 2002; 21: HEART TRANSPLANTATION Pediatric Recipients.

HEART TRANSPLANTATION Pediatric Recipients 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

HEART TRANSPLANTATION

HEART-LUNG TRANSPLANTATION Overall 2010 ISHLT J Heart Lung Transplant Oct; 29 (10):

HEART TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26:

HEART-LUNG TRANSPLANTATION

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2005 J Heart Lung Transplant 2005;24:

2004 ISHLT J Heart Lung Transplant 2004; 23: HEART TRANSPLANTATION Overall.

HEART TRANSPLANTATION Pediatric Recipients ISHLT 2008 J Heart Lung Transplant 2008;27:

HEART TRANSPLANTATION Overall ISHLT 2005 J Heart Lung Transplant 2005;24:

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2007 J Heart Lung Transplant 2007;26.

HEART-LUNG TRANSPLANTATION

County-level Estimates of Leisure Time Physical Inactivity among Adults aged 20 years old Trends

EU Market Situation for Eggs and Poultry Management Committee 21 June 2012.

COMPUTER B Y : L K. WINDOWS INFORMATION B Y : L K.

Name ____________________ Date ___________ Period ____.

©Brooks/Cole, 2001 Chapter 12 Derived Types-- Enumerated, Structure and Union.

PSSA Preparation.

Immunobiology: The Immune System in Health & Disease Sixth Edition

UK Renal Registry 17th Annual Report Figure 5.1. Trend in one year after 90 day incident patient survival by first modality, 2003–2012 cohorts (adjusted.

HEART TRANSPLANTATION Adult Recipients JHLT Oct; 32(10):

HEART-LUNG TRANSPLANTATION Overall 2014 JHLT Oct; 33(10):

Optimizing lung transplant outcomes in the adult and pediatric patient. Cynthia S. Herrington, MD Associate Professor of Surgery Keck School of Medicine.

HEART-LUNG TRANSPLANTATION Overall ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant Oct; 31(10):

HEART-LUNG TRANSPLANTATION Pediatric Recipients 2015 JHLT Oct; 34(10):

Kaplan-Meier survival for adult heart transplants performed between January 1982 and June 2006 by era. All comparisons are significant at p < (Reproduced.

HEART-LUNG TRANSPLANTATION

HEART TRANSPLANTATION

HEART TRANSPLANTATION

LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2010

HEART-LUNG TRANSPLANTATION

HEART-LUNG TRANSPLANTATION

HEART-LUNG TRANSPLANTATION

HEART-LUNG TRANSPLANTATION

A: Comparison of pediatric lung transplant survival between different age groups. A: Comparison of pediatric lung transplant survival between different.

HEART-LUNG TRANSPLANTATION

Presentation transcript:

J Heart Lung Transplant 2009;28: HEART TRANSPLANTATION Overall ISHLT 2009

J Heart Lung Transplant 2009;28: NUMBER OF HEART TRANSPLANTS REPORTED BY YEAR ISHLT NOTE: This figure includes only the heart transplants that are reported to the ISHLT Transplant Registry. As such, the presented data may not mirror the changes in the number of heart transplants performed worldwide 2009

J Heart Lung Transplant 2009;28: NUMBER OF HEART TRANSPLANTS REPORTED BY YEAR ISHLT NOTE: This figure includes only the heart transplants that are reported to the ISHLT Transplant Registry. As such, the presented data may not mirror the changes in the number of heart transplants performed worldwide 2009

J Heart Lung Transplant 2009;28: AVERAGE CENTER VOLUME Heart Transplants: January 1, 2003 – June 30, 2008 ISHLT 2009

J Heart Lung Transplant 2009;28: HEART TRANSPLANTS: Donor Age by Year of Transplant ISHLT 2009

J Heart Lung Transplant 2009;28: AGE DISTRIBUTION OF HEART TRANSPLANT RECIPIENTS BY ERA P < ISHLT 2009

J Heart Lung Transplant 2009;28: HEART TRANSPLANTATION Kaplan-Meier Survival (1/1982-6/2005) ISHLT N at risk at 22 years: 145 HEART TRANSPLANTATION Kaplan-Meier Survival (1/1982-6/2007) 2009

J Heart Lung Transplant 2009;28: HEART TRANSPLANTATION Adult Recipients ISHLT 2009

J Heart Lung Transplant 2009;28: DIAGNOSIS IN ADULT HEART TRANSPLANTS ISHLT 2009

J Heart Lung Transplant 2009;28: (N=36,458) /2008 (N=18,798) p-value Recipient age (years)51.4 ± 11.0 ( )51.1 ± 12.4 ( ) Donor age (years)32.3 ± 12.8 ( )33.6 ± 13.0 ( )< Recipient/donor gender (% male)80.0%/ 67.8%77.3%/ 69.5%<0.0001/ < Recipient weight (kg)76.0 ± 14.4 ( )78.3 ± 15.5 ( )< Recipient height (cm)172.7 ± 8.7 ( )172.9 ± 8.9 ( ) Recipient BMI25.3 ± 4.1 ( )26.0 ± 4.3 ( )< Recipient/donor diabetes mellitus13.1%/ 1.6%22.0%/ 2.2%<0.0001/ < Recipient amiodarone use (US only) 22.6%29.0%< Recipient/donor cigarette history18.5%/ 37.5%44.9%/ 25.2%<0.0001/ < Ischemic time (hours)2.5 ± 1.4 ( )2.8 ± 1.5 ( )< Most recent PRA > 10%* Overall7.8%9.0% Class I12.3% Class II8.5% ISHLT Continuous factors are expressed as mean ± standard deviation (range) ADULT HEART TRANSPLANTATION Characteristics of Donors, Recipients and Transplants * Until mid-2004 PRA was collected as a single percentage. After this date, PRA was collected separately for Class I and Class II. 2009

J Heart Lung Transplant 2009;28: (N=36,458) /2008 (N=18,798) p-value Creatinine at time of transplant1.3 ± 0.5 ( ) Pulmonary vascular resistance (Wood units) 2.8 ± 1.5 ( )2.6 ± 1.4 ( )< HLA Mismatches %4.3% %40.5% %55.2% Diagnosis < Coronary artery disease45.2%39.5% Cardiomyopathy45.9%49.5% Valvular3.2%2.4% Retransplant1.9%2.3% Congenital1.8%2.4% Other causes1.9%3.8% ISHLT Data are expressed as mean ± standard deviation (range) ADULT HEART TRANSPLANTATION Characteristics of Donors, Recipients and Transplants (Contd) 2009

J Heart Lung Transplant 2009;28: (N=36,458) /2008 (N=18,798) p-value Donor cause of death < Head trauma45.2%52.1% Stroke28.4%29.6% Other26.5%18.3% Pre-operative support (multiple items may be reported) Hospitalized at time of transplant58.6%46.4%< On IV inotropes48.9%44.8%< LVAD4.1%19.0%< IABP6.8%6.9% RVAD0.1%2.9%< Ventilator3.1%2.9% TAH0.4% ECMO0.3%0.7%< ISHLT ADULT HEART TRANSPLANTATION Characteristics of Donors, Recipients and Transplants (Contd) 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS: RECIPIENT AGE DISTRIBUTION BY LOCATION Transplants between January 2000 and June 2008 ISHLT 2009 Mean/median recipient age: Europe = 50.8/53.0 North America = 51.7/54.0 Other = 48.4/51.0

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS: DONOR AGE DISTRIBUTION BY LOCATION Transplants between January 2000 and June 2008 ISHLT 2009 Mean/median donor age: Europe = 38.0/39.0 North America = 31.6/29.0 Other = 33.0/32.0

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2007) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Conditional Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2007) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Age Group (Transplants: 1/1982-6/2007) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Age Group (Transplants: 1/2002-6/2007) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Diagnosis (Transplants: 1/1982-6/2007) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2007) Diagnosis: Cardiomyopathy ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2007) Diagnosis: Coronary Artery Disease ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2007) Diagnosis: Congenital ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2007) Diagnosis: Retransplant ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: 1/1982 – 6/2007) Diagnosis: Valvular ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Diagnosis Conditional on Survival to 1 Year (Transplants: 1/1982-6/2007) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Diagnosis (Transplants: 1/2002-6/2007) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Diagnosis Conditional on Survival to 1 Year (Transplants: 1/2002-6/2007) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by PVR (Transplants: 1/2002-6/2007) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by PVR (Transplants: 1/2002-6/2007) PVR: 1- < 3 Wood units ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by PVR (Transplants: 1/2002-6/2007) PVR: 3- < 5 Wood units ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by PVR (Transplants: 1/2002-6/2007) PVR: 5+ Wood units ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by VAD usage (Transplants: 4/1994-6/2007) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by VAD usage (Transplants: 1/2002-6/2007) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by VAD usage (Transplants: 1/1999-6/2007) Conditional on Survival to 6 Months ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by VAD usage and Era (Transplants: 1/1999-6/2007) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART RE-TRANSPLANTS 1-Year Survival ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART RECIPIENTS Functional Status of Surviving Recipients (Follow-ups: June 2008) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART RECIPIENTS Functional Status of Surviving Recipients For the Same Patients (Follow-ups: June 2008) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART RECIPIENTS Employment Status of Surviving Recipients (Follow-ups: June 2008) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART RECIPIENTS Employment Status of Surviving Recipients Age at Follow-up: Years (Follow-ups: June 2008) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART RECIPIENTS Rehospitalization Post-transplant of Surviving Recipients (Follow-ups: June 2008) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART RECIPIENTS Induction Immunosuppression (Transplants: January 2002 – June 2008) ISHLT Analysis is limited to patients who were alive at the time of the follow-up 2009

J Heart Lung Transplant 2009;28: ADULT HEART RECIPIENTS Induction Immunosuppression (Transplants: 1997, 2002 and 1/2008-6/2008) ISHLT Analysis is limited to patients who were alive at the time of the follow-up 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival by Induction Type (Transplants: 1/2000-6/2007, conditional on survival to 14 days) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART RECIPIENTS Maintenance Immunosuppression at Time of Follow-up (Follow-ups: January June 2008) NOTE: Different patients are analyzed in Year 1 and Year 5 ISHLT Analysis is limited to patients who were alive at the time of the follow-up 2009

J Heart Lung Transplant 2009;28: ADULT HEART RECIPIENTS Maintenance Immunosuppression at Time of Follow-up For the Same Patients (Follow-ups: January June 2008) ISHLT Analysis is limited to patients who were alive at the time of the follow-up 2009

J Heart Lung Transplant 2009;28: ADULT HEART RECIPIENTS Maintenance Immunosuppression at Time of 1 Year Follow-up NOTE: Different patients are analyzed in each time frame. ISHLT Analysis is limited to patients who were alive at the time of the follow-up 2009

J Heart Lung Transplant 2009;28: ADULT HEART RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up (Follow-ups: January June 2008) NOTES: Different patients are analyzed in Year 1 and Year 5. In the Year 1 cohort 72.55% of patients were on prednisone; in the Year 5 cohort 52.13% of patients were on prednisone. ISHLT Analysis is limited to patients who were alive at the time of the follow-up 2009

J Heart Lung Transplant 2009;28: ADULT HEART RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up For the Same Patients (Follow-ups: January June 2008) ISHLT Analysis is limited to patients who were alive at the time of the follow-up 2009

J Heart Lung Transplant 2009;28: PERCENTAGE OF ADULT HEART TRANSPLANT RECIPIENTS EXPERIENCING REJECTION BETWEEN TRANSPLANT DISCHARGE AND 1-YEAR FOLLOW-UP Stratified by Type of Induction (Follow-ups: July 1, June 30, 2008) ISHLT Overall FemaleMale No induction: N=3,133 Polyclonal: 1,304 IL2R-antagonist: N=1,866 OKT3: N=161 Overall: no induct vs. poly (p<0.0001); no induct vs. IL2 (p<0.0001), no induct vs. OKT3 (p=0.048), poly vs. IL2 (p=0.038) 18-44: no induct vs. poly (p=0.009); no induct vs. IL2 (p=0.001) 45-62: no induct vs. poly (p=0.024); no induct vs. IL2 (p<0.0001) 63+: no induct vs. poly (p=0.015); no induct vs. IL2 (p<0.0001); no induct vs. OKT3 (p=0.002) F: no induct vs. poly (p=0.001); no induct vs. IL2 (p<0.0001) M: no induct vs. poly (p=0.011); no induct vs. IL2 (p<0.0001); poly vs. IL2 (p=0.021) Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. 2009

J Heart Lung Transplant 2009;28: PERCENTAGE OF ADULT HEART TRANSPLANT RECIPIENTS EXPERIENCING REJECTION BETWEEN TRANSPLANT DISCHARGE AND 1-YEAR FOLLOW-UP Stratified by Maintenance Immunosuppression (Follow-ups: July 1, June 30, 2008 ) Overall: p < : p < : p < Female: p = Male: p < ISHLT NOTE: There were 149 patients with cyclosporine+AZA and 41 with tacrolimus+AZA. These groups were excluded due to small numbers. Cyclosporine + MMF: N = 2,360 Tacrolimus + MMF: N = 3, MaleFemaleOverall Analysis is limited to patients who were alive at the time of the follow-up Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTATION Kaplan-Meier Survival Stratified by Treatment for Rejection Within 1 st Year Conditional on survival to 1 year (follow-ups: 7/2004-6/2007) ISHLT Treated rejection = Recipient was reported to (1) have at least one acute rejection episode that was treated with an anti- rejection agent; or (2) have been hospitalized for rejection. No rejection = Recipient had (i) no acute rejection episodes and (ii) was reported either as not hospitalized for rejection or did not receive anti-rejection agents. 2009

J Heart Lung Transplant 2009;28: POST-HEART TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors at 1, 5 and 10 Years Post- Transplant (Follow-ups: April June 2008) ISHLT 2009

J Heart Lung Transplant 2009;28: POST-HEART TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors at 1, 5 and 10 Years Post- Transplant (Transplants: June 1998) For the Same Patients ISHLT 2009

J Heart Lung Transplant 2009;28: POST-HEART TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors within 1 and 5 Years Post-Transplant (Transplants: June 2003) For the Same Patients ISHLT 2009

J Heart Lung Transplant 2009;28: FREEDOM FROM CARDIAC ALLOGRAFT VASCULOPATHY For Adult Heart Recipients (Transplants: April 1994-June 2007) ISHLT 2009

J Heart Lung Transplant 2009;28: FREEDOM FROM SEVERE RENAL DYSFUNCTION BY ERA* For Adult Heart Recipients (Transplants: April 1994-June 2007) ISHLT 2009

J Heart Lung Transplant 2009;28: PATIENT SURVIVAL AFTER REPORT OF CAV AND PATIENT SURVIVAL IN PATIENTS WITHOUT CAV* (Transplants: April 1994-June 2007) ISHLT * Patients without CAV conditioned on survival to median time of CAV development (501 days) 2009

J Heart Lung Transplant 2009;28: PATIENT SURVIVAL AFTER REPORT OF CAV AND PATIENT SURVIVAL IN PATIENTS WITHOUT CAV* BY ERA (Transplants: April 1994-June 2007) ISHLT * Patients without CAV conditioned on survival to median time of CAV development (501 days) 2009

J Heart Lung Transplant 2009;28: MALIGNANCY POST-HEART TRANSPLANTATION FOR ADULTS Cumulative Prevalence in Survivors (Follow-ups: April June 2008) Malignancy/Type1-Year Survivors 5-Year Survivors 10-Year Survivors No Malignancy23,626 (97.2%)9,619 (85.6%)2,074 (69.4%) Malignancy (all types combined)676 (2.8%)1,618 (14.4%)913 (30.6%) Malignancy Type Skin Lymph Other Type Not Reported Other includes: prostate (11, 32, 17), adenocarcinoma (6, 3, 1), lung (6, 5, 1), bladder (4, 5, 4), Kaposi's sarcoma (1, 3, 1), breast (2, 7, 2), cervical (2, 4, 2), colon (2, 3, 1), and renal (2, 7, 2). Numbers in parentheses are those reported within 1 year, 5 years and 10 years, respectively. ISHLT NOTE: Multiple types may be reported; sum of types may be greater than total number with malignancy. 2009

J Heart Lung Transplant 2009;28: FREEDOM FROM MALIGNANCY For Adult Heart Recipients (Follow-ups: April June 2008) ISHLT 2009

J Heart Lung Transplant 2009;28: FREEDOM FROM MALIGNANCY For Adult Heart Recipients (Transplants : April June 2007) ISHLT 2009

J Heart Lung Transplant 2009;28: FREEDOM FROM LYMPHOMA For Adult Heart Recipients (Transplants : April June 2007) ISHLT 2009

J Heart Lung Transplant 2009;28: FREEDOM FROM SKIN MALIGNANCY For Adult Heart Recipients (Transplants : April June 2007) ISHLT 2009

J Heart Lung Transplant 2009;28: FREEDOM FROM OTHER MALIGNANCY For Adult Heart Recipients (Transplants : April June 2007) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANT RECIPIENTS: Cause of Death (Deaths: January June 2008) CAUSE OF DEATH 0-30 Days (N = 3,531) 31 Days – 1 Year (N = 3,513) >1 Year – 3 Years (N = 2,716) >3 Years – 5 Years (N = 2,356) >5 Years – 10 Years (N = 5,335 ) >10 Years (N = 3,677) CARDIAC ALLOGRAFT VASCULOPATHY 62 (1.8%)163 (4.6%)383 (14.1%)369 (15.7%)767 (14.4%)520 (14.1%) ACUTE REJECTION227 (6.4%)427 (12.2%)274 (10.1%)104 (4.4%)88 (1.6%)33 (0.9%) LYMPHOMA1 (0.0%)66 (1.9%)93 (3.4%)103 (4.4%)246 (4.6%)145 (3.9%) MALIGNANCY, OTHER4 (0.1%)78 (2.2%)301 (11.1%)440 (18.7%)999 (18.7%)690 (18.8%) CMV4 (0.1%)43 (1.2%)17 (0.6%)4 (0.2%)6 (0.1%)1 (0.0%) INFECTION, NON-CMV458 (13.0%)1,066 (30.3%)343 (12.6%)229 (9.7%)570 (10.7%)361 (9.8%) GRAFT FAILURE1,452 (41.1%)626 (17.8%)636 (23.4%)473 (20.1%)965 (18.1%)609 (16.6%) TECHNICAL253 (7.2%)38 (1.1%)19 (0.7%)17 (0.7%)41 (0.8%)33 (0.9%) OTHER209 (5.9%)303 (8.6%)272 (10.0%)220 (9.3%)531 (10.0%)364 (9.9%) MULTIPLE ORGAN FAILURE 451 (12.8%)386 (11.0%)135 (5.0%)122 (5.2%)369 (6.9%)293 (8.0%) RENAL FAILURE23 (0.7%)34 (1.0%)43 (1.6%)86 (3.7%)309 (5.8%)308 (8.4%) PULMONARY150 (4.2%)137 (3.9%)105 (3.9%)112 (4.8%)218 (4.1%)165 (4.5%) CEREBROVASCULAR 237 (6.7%)146 (4.2%)95 (3.5%)77 (3.3%)226 (4.2%)155 (4.2%) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANT RECIPIENTS: Cause of Death from Leading Causes by Era (Deaths: January June 2008) CAUSE OF DEATH DATE OF DEATH 0-30 Days (N = 3,531) 31 Days – 1 Year (N = 3,513) >1 Year – 3 Years (N = 2,716) >3 Years – 5 Years (N = 2,356) >5 Years – 10 Years (N = 5,335) >10 Years (N = 3,677) ACUTE REJECTION (7.4%)267 (14.6%)123 (8.9%)42 (4.0%)21 (1.3%)3 (1.5%) / (5.4%)160 (9.5%)151 (11.3%)62 (4.7%)67 (1.8%)30 (0.9%) CARDIAC ALLOGRAFT VASCULOPATHY (2.1%)100 (5.5%)224 (16.3%)222 (21.3%)314 (19.2%)47 (24.2%) / (1.3%)63 (3.7%)159 (11.9%)147 (11.2%)453 (12.2%)473 (13.6%) GRAFT FAILURE (44.0%)383 (21.0%)326 (23.7%)186 (17.8%)299 (18.3%)33 (17.0%) / (38.1%)243 (14.4%)310 (23.2%)287 (21.9%)666 (18.0%)576 (16.5%) MALIGNANCY, OTHER (0.2%)49 (2.7%)158 (11.5%)202 (19.3%)303 (18.5%)26 (13.4%) /20080 (0.0%)29 (1.7%)143 (10.7%)238 (18.1%)696 (18.8%)664 (19.1%) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANT RECIPIENTS: Relative Incidence of Leading Causes of Death (Deaths: January June 2008) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANT RECIPIENTS: Cumulative Incidence of Leading Causes of Death (Transplants: January June 2007) ISHLT 2009

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Risk Factors for 1 Year Mortality 2009 ISHLT (N=10,705) * Temporary circulatory support includes ECMO and Abiomed. NOTE: There were too few continuous flow devices to analyze.

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Risk Factors for 1 Year Mortality 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Age 2009 ISHLT (N=10,705)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor Age 2009 ISHLT (N=10,705)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient BMI 2009 ISHLT (N=10,705)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor BMI 2009 ISHLT (N=10,705)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Relative Risk of 1 Year Mortality with 95% Confidence Limits Ischemia Time 2009 ISHLT (N=10,705)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Relative Risk of 1 Year Mortality with 95% Confidence Limits Center Volume 2009 ISHLT (N=10,705)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Bilirubin 2009 ISHLT (N=10,705)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Creatinine (N=10,705) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient PCW (N=10,705) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient PVR (N=10,705) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Factors Not Significant for 1 Year Mortality Recipient Factors: Prior malignancy, hospitalized, prior pregnancy, balloon pump, diabetes, PRA Donor Factors: Clinical infection, history of diabetes, gender, history of hypertension, cause of death, history of malignancy Transplant Factors: HLA mismatch, CMV mismatch, prior transplant 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=18-30 Years Risk Factors for 1 Year Mortality (N=932) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=18-30 Years Risk Factors for 1 Year Mortality 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=18-30 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Age (N=932) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=18-30 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor Age (N=932) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=18-30 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Height (N=932) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=18-30 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Creatinine (N=932) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=18-30 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient PA Diastolic Pressure (N=932) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=31-60 Years Risk Factors for 1 Year Mortality (N=7,113) * Temporary circulatory support includes ECMO and Abiomed. NOTE: There were too few continuous flow devices to analyze ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007 ) Recipients: Age=31-60 Years Borderline Significant Risk Factors for 1 Year Mortality (N=7,113) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=31-60 Years Risk Factors for 1 Year Mortality 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Age (N=7,113) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor Age (N=7,113) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Height (N=7,113) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits BSA Ratio (N=7,113) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Creatinine (N=7,113) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Bilirubin (N=7,113) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient PCW Pressure (N=7,113) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient PVR (N=7,113) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=31-60 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Ischemia Time (N=7,113) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=61-75 Years Risk Factors for 1 Year Mortality (N=2,646) * Temporary circulatory support includes ECMO and Abiomed. NOTE: There were too few continuous flow devices to analyze ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007 ) Recipients: Age=61-75 Years Borderline Significant Risk Factors for 1 Year Mortality (N=2,646) * Other diagnosis = diagnoses other than cardiomyopathy, coronary artery disease, valvular heart disease and retransplant ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=61-75 Years Risk Factors for 1 Year Mortality 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient Age (N=2,646) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor Age (N=2,646) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Recipient BSA (N=2,646) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Donor BSA (N=2,646) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits BMI Ratio (N=2,646) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Creatinine (N=2,646) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Pre-Transplant Bilirubin (N=2,646) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Ischemia Time (N=2,646) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Recipients: Age=61-75 Years Relative Risk of 1 Year Mortality with 95% Confidence Limits Center Volume (N=2,646) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2002-6/2007) Relative Risk of 1 Year Mortality with 95% Confidence Limits by Recipient Age Group Ischemia Time 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Risk Factors for 5 Year Mortality 2009 ISHLT (N=7,171) * Temporary circulatory support includes ECMO and Abiomed NOTE: There were too few continuous flow devices to analyze.

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Risk Factors for 5 Year Mortality 2009 ISHLT (N=7,171)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Relative Risk of 5 Year Mortality with 95% Confidence Limits Recipient Age 2009 ISHLT (N=7,171)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Relative Risk of 5 Year Mortality with 95% Confidence Limits Donor Age 2009 ISHLT (N=7,171)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Relative Risk of 5 Year Mortality with 95% Confidence Limits Ischemia Time 2009 ISHLT (N=7,171)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Relative Risk of 5 Year Mortality with 95% Confidence Limits Center Volume 2009 ISHLT (N=7,171)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Relative Risk of 5 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Height 2009 ISHLT (N=7,171)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Relative Risk of 5 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Bilirubin 2009 ISHLT (N=7,171)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Relative Risk of 5 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Creatinine 2009 ISHLT (N=7,171)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Relative Risk of 5 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant PA Mean Pressure 2009 ISHLT (N=7,171)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Factors Not Significant for 5 Year Mortality Recipient Factors: Sternotomy, pulmonary embolism, IV inotropes, transfusions, prior malignancy, PRA, balloon pump, infection requiring IV antibiotics prior to transplant Donor Factors: History of cancer, clinical infection, cause of death, history of hypertension, height, weight Transplant Factors: CMV mismatch, ABO match 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year 2009 ISHLT (N=5,857)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year 2009 ISHLT (N=5,857)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year Recipient Age 2009 ISHLT (N=5,857)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year Donor Age 2009 ISHLT (N=5,857)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year Recipient Weight 2009 ISHLT (N=5,857)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2000-6/2003) Relative Risk of 5 Year Mortality with 95% Confidence Limits Conditional on Survival to 1 Year Center Volume 2009 ISHLT (N=5,857)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1994-6/1998) Risk Factors for 10 Year Mortality 2009 ISHLT (N=8,818)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1994-6/1998) Risk Factors for 10 Year Mortality (N=8,818) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1994-6/1998) Relative Risk of 10 Year Mortality with 95% Confidence Limits Recipient Age (N=8,818) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1994-6/1998) Relative Risk of 10 Year Mortality with 95% Confidence Limits Donor Age (N=8,818) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1994-6/1998) Relative Risk of 10 Year Mortality with 95% Confidence Limits Pre-Transplant Recipient BMI (N=8,818) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1994-6/1998) Relative Risk of 10 Year Mortality with 95% Confidence Limits Donor BMI (N=8,818) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1994-6/1998) Relative Risk of 10 Year Mortality with 95% Confidence Limits Ischemia Time (N=8,818) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1994-6/1998) Relative Risk of 10 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Creatinine (N=8,818) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1994-6/1998) Relative Risk of 10 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant Bilirubin (N=8,818) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1994-6/1998) Relative Risk of 10 Year Mortality with 95% Confidence Limits Center Volume (N=8,818) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1994-6/1998) Risk Factors for 10 Year Mortality Conditional on Survival to 3 Years 2009 ISHLT (N=6,175)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS Risk Factors for 10 Year Mortality Conditional on Survival to 3 Years 2009 ISHLT (N=6,175)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1994-6/1998) Relative Risk of 10 Year Mortality with 95% Confidence Limits Conditional on Survival to 3 Years Recipient Age 2009 ISHLT (N=6,175)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1994-6/1998) Relative Risk of 10 Year Mortality with 95% Confidence Limits Conditional on Survival to 3 Years Recipient Pre-Transplant Creatinine 2009 ISHLT (N=6,175)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1994-6/1998) Relative Risk of 10 Year Mortality with 95% Confidence Limits Conditional on Survival to 3 Years Donor BMI 2009 ISHLT (N=6,175)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1994-6/1998) Relative Risk of 10 Year Mortality with 95% Confidence Limits Conditional on Survival to 3 Years Recipient Pre-Transplant PA Mean Pressure 2009 ISHLT (N=6,175)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1989-6/1993) Risk Factors for 15 Year Mortality (N=7,478) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1989-6/1993) Borderline Significant Risk Factors for 15 Year Mortality (N=7,478) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS Risk Factors for 15 Year Mortality (N=7,478) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1989-6/1993) Relative Risk of 15 Year Mortality with 95% Confidence Limits Recipient Age (N=7,478) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1989-6/1993) Relative Risk of 15 Year Mortality with 95% Confidence Limits Donor Age (N=7,478) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1989-6/1993) Relative Risk of 15 Year Mortality with 95% Confidence Limits Ischemia Time (N=7,478) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1989-6/1993) Relative Risk of 15 Year Mortality with 95% Confidence Limits Recipient Pre-Transplant PRA (N=7,478) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1989-6/1993) Relative Risk of 15 Year Mortality with 95% Confidence Limits Center Volume (N=7,478) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1989-6/1993) Risk Factors for 15 Year Mortality Conditional on Survival to 5 Years 2009 ISHLT (N=4,816)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS Risk Factors for 15 Year Mortality Conditional on Survival to 5 Years 2009 ISHLT (N=4,816)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1989-6/1993) Relative Risk of 15 Year Mortality with 95% Confidence Limits Conditional on Survival to 5 Years Recipient Age 2009 ISHLT (N=4,816)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1989-6/1993) Relative Risk of 15 Year Mortality with 95% Confidence Limits Conditional on Survival to 5 Years Donor Age 2009 ISHLT (N=4,816)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1989-6/1993) Relative Risk of 15 Year Mortality with 95% Confidence Limits Conditional on Survival to 5 Years Recipient Pre-Transplant PRA (%) 2009 ISHLT (N=4,816)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1982-6/1987) Risk Factors for 20 Year Mortality (N=4,487) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS Risk Factors for 20 Year Mortality (N=4,487) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1982-6/1987) Relative Risk of 20 Year Mortality with 95% Confidence Limits Recipient Age (N=4,487) 2009 ISHLT

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2001-6/2007) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant (N=9,750) ISHLT 2009 *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2001-6/2007) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction Pre-Transplant ISHLT 2009 (N=9,750) *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2001-6/2007) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant Recipient Age ISHLT 2009 (N=9,750) *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2001-6/2007) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant Recipient Pre-Transplant Creatinine ISHLT 2009 (N=9,750) *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (1/2001-6/2007) Risk Factors for Developing Renal Dysfunction within 1 Year Limited to Recipients without Severe Renal Dysfunction* Pre-Transplant Height Difference ISHLT 2009 (N=9,750) *Severe renal dysfunction = creatinine > 2.5 mg/dl or dialysis

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1996-6/2000) Risk Factors for Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge (N=5,672) ISHLT 2009

J Heart Lung Transplant 2009;28: ISHLT 2009 (N=5,672) ADULT HEART TRANSPLANTS (7/1996-6/2000) Risk Factors for Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1996-6/2000) Relative Risk of Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Recipient Age ISHLT 2009 (N=5,672)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1996-6/2000) Relative Risk of Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Height Difference ISHLT 2009 (N=5,672)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1996-6/2000) Relative Risk of Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Donor Age, Donor Gender and Recipient Gender ISHLT 2009 (N=5,672) Relative risk includes impact of donor gender, recipient gender and donor age.

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1996-6/2000) Relative Risk of Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Recipient Pre-Transplant PCW ISHLT 2009 (N=5,672)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1996-6/2000) Relative Risk of Developing Cardiac Allograft Vasculopathy within 8 Years Conditional on Survival to Transplant Discharge Center Volume ISHLT 2009 (N=5,672)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1996-6/2000) Risk Factors for Developing Non-Skin Malignancy within 8 Years Limited to Recipients without History of Malignancy Pre-Transplant and Conditional on Survival to Transplant Discharge (N=4,904) ISHLT 2009

J Heart Lung Transplant 2009;28: ISHLT 2009 (N=4,904) ADULT HEART TRANSPLANTS (7/1996-6/2000) Risk Factors for Developing Non-Skin Malignancy within 8 Years Limited to Recipients without History of Malignancy Pre-Transplant and Conditional on Survival to Transplant Discharge

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1996-6/2000) Relative Risk for Developing Non-Skin Malignancy within 8 Years Limited to Recipients without History of Malignancy Pre-Transplant and Conditional on Survival to Transplant Discharge Recipient Age ISHLT 2009 (N=4,904)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1996-6/2000) Relative Risk for Developing Non-Skin Malignancy within 8 Years Limited to Recipients without History of Malignancy Pre-Transplant and Conditional on Survival to Transplant Discharge Recipient Height ISHLT 2009 (N=4,904)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1996-6/2000) Relative Risk for Developing Non-Skin Malignancy within 8 Years Limited to Recipients without History of Malignancy Pre-Transplant and Conditional on Survival to Transplant Discharge Donor BSA ISHLT 2009 (N=4,904)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1996-6/2000) Relative Risk for Developing Non-Skin Malignancy within 8 Years Limited to Recipients without History of Malignancy Pre-Transplant and Conditional on Survival to Transplant Discharge Recipient Bilirubin ISHLT 2009 (N=4,904)

J Heart Lung Transplant 2009;28: ADULT HEART TRANSPLANTS (7/1996-6/2000) Relative Risk for Developing Non-Skin Malignancy within 8 Years Limited to Recipients without History of Malignancy Pre-Transplant and Conditional on Survival to Transplant Discharge Center Volume ISHLT 2009 (N=4,904)